The executive who brought Novo Nordisk A/S’s first weight-loss shot to market is coming back as chairman of the Danish drugmaker, and not all shareholders are happy about it.
Investors are meeting on Friday to elect Lars Rebien Sorensen to lead the supervisory board less than a week after Novo lost a bidding war with Pfizer Inc. The outcome is a foregone conclusion as the Dane, who ran the company for 16 years, also heads the Novo Nordisk Foundation, the controlling shareholder that holds 77% of Novo’s voting rights.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.